[Combination of antimetabolites and alkylating agents in the treatment of advanced breast cancer].

An association of 5-fluoruracyl (or methotrexate) and cyclophosphamide was used in the treatment of 20 cases of hormone-resistant breast cancer. Five objective regressions were obtained. Mean survival here was 28.25 (S.D. 2.87) months, as opposed to 12.75 (S.D. 6.93) months in the remainder. Side-effects of various kinds were noted in 9 patients.
AuthorsR Germiniani, G Pipino, F Lavorato, S Bressani Doldi
JournalMinerva medica (Minerva Med) Vol. 68 Issue 13 Pg. 831-4 (Mar 17 1977) ISSN: 0026-4806 [Print] ITALY
Vernacular TitleL'associazione di antimetaboliti ed alchilanti nel trattamento del cancro mammario in fase avanzata
PMID321989 (Publication Type: Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Alkylating Agents
  • Antimetabolites
  • Cyclophosphamide
  • Fluorouracil
  • Adult
  • Aged
  • Alkylating Agents (therapeutic use)
  • Antimetabolites (therapeutic use)
  • Breast Neoplasms (drug therapy)
  • Clinical Trials as Topic
  • Cyclophosphamide (administration & dosage, therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Fluorouracil (administration & dosage, therapeutic use)
  • Humans
  • Middle Aged
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: